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Abstract
The chemotherapy of lymphatic filariasis relies upon drugs such as diethylcarbamazine and ivermectin that largely target
the microfilarial stages of the parasite, necessitating continued treatment over the long reproductive life span of the adult
worm. The identification of compounds that target adult worms has been a long-term goal of WHO. Here we describe a
fluorescence polarization assay for the identification of compounds that target Hsp90 in adult filarial worms. The assay was
originally developed to identify inhibitors of Hsp90 in tumor cells, and relies upon the ability of small molecules to inhibit
the binding of fluorescently labelled geldanamycin to Hsp90. We demonstrate that the assay works well with soluble
extracts of Brugia, while extracts of the free-living nematode C. elegans fail to bind the probe, in agreement with data from
other experiments. The assay was validated using known inhibitors of Hsp90 that compete with geldanamycin for binding
to Hsp90, including members of the synthetic purine-scaffold series of compounds. The efficacy of some of these
compounds against adult worms was confirmed in vitro. Moreover, the assay is sufficiently sensitive to differentiate between
binding of purine-scaffold compounds to human and Brugia Hsp90. The assay is suitable for high-throughput screening and
provides the first example of a format with the potential to identify novel inhibitors of Hsp90 in filarial worms and in other
parasitic species where Hsp90 may be a target.
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Introduction
Lymphatic filariasis (LF) caused by the nematode parasites
Wuchereria bancrofti and Brugia malayi remains a major tropical
disease with an estimated 120 M individuals infected [1]. The
infection is transmitted to humans by the bite of a mosquito
carrying infective third stage larvae (L3) in the head and
mouthparts. The L3 enter the lymphatics and develop through
two moults to sexually mature adults; following mating, the adult
female worm produces an abundance of first stage larvae (L1 or
microfilariae, Mf) which circulate in the bloodstream and which
represent the reservoir of infection for the mosquito host. There
are no vaccines available for preventing infection. The control of
LF is not easy and relies upon drugs that largely target the Mf,
such as diethylcarbamazine (DEC), a drug developed in 1947 [2],
or ivermectin. This necessitates continued treatment over the long
reproductive life span of the worm, as Mf re-populate the blood
stream from adult worms that are largely unaffected by these
drugs. The development of a macrofilaricidal compound has long
been a goal of the World Health Organization (WHO), but
attempts to develop appropriate compounds have yet to be
successful [3]. Meanwhile the ongoing campaign for the global
elimination of LF is based on the use of DEC, or ivermectin in sub-
Saharan Africa where LF overlaps with onchocerciasis, together
with albendazole, a drug with known efficacy against gastro-
intestinal nematodes but with limited efficacy against filariae [4].
The availability of a macrofilaricidal drug would obviate the need
for continued treatment with microfilaricidal drugs. As well as the
financial implications of long-term drug delivery programmes,
repeated exposure to chemotherapy poses credible risks for the
development of resistance, as is apparent from the reduced efficacy
of ivermectin in some onchocerciasis patients [5].
Despite the fact that DEC and more recently ivermectin have
been extensively used to treat LF, their precise mode of action
remains unclear. In fact there is a dearth of information on
appropriate drug targets for the chemotherapy of LF, and while
the mode of action of ivermectin on the free-living model
nematode Caenorhabditis elegans is well-documented [6,7] its target
in parasitic nematodes is still open to debate [8,9]. The only novel
chemotherapeutic target in filarial nematodes currently under
development is the Wolbachia endosymbiont [10,11]. However, the
availability of the B. malayi genome sequence [12] may facilitate
the identification of novel drug targets [13]. The dearth of drugs
available to treat LF, and indeed other helminth infections of
humans [1] reflects a number of limitations: the lack of availability
of high-throughput screening (HTS) systems, our limited knowl-
edge of how existing drugs kill filarial worms, and the paucity of
investment in these specific areas.
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as a possible target in LF [14]. Hsp90 is a validated drug target in
many cancers [15], and an emerging target in neurodegenerative
diseases [16] and in viral and fungal infections [17]. It has an
unusual ATP-binding pocket in the N-terminal domain, and
several small molecules that bind competitively with ATP in this
site inhibit its function [18]. With inhibitor bound, the
conformation adopted by Hsp90 destabilises client proteins, which
are then targeted for degradation via the proteasome pathway
[15]. As many clients of Hsp90 are essential proteins within cells of
pathogenic function, inhibition of the Hsp90 pathway is invariably
lethal to these, but not to normal cells [15].
Exposure of Brugia pahangi to geldanamycin (GA), a specific
inhibitor of Hsp90 [18], kills adult worms and Mf in vitro.
Interestingly, this agent has no significant effect on the related
nematode Caenorhabditis elegans [19], despite a high degree of
conservation between the two Hsp90 sequences [20]. The low
affinity of C. elegans Hsp90 for GA is supported by studies in yeast,
as an hsp90 null strain complemented with C. elegans hsp90 is
relatively resistant to GA [21]. In contrast, expression of C. elegans
Hsp90 in mammalian cells does not confer GA-resistance on the
cells, as the nematode Hsp90 forms hetero-dimers with the
endogenous (GA sensitive) Hsp90, thus retaining sensitivity to GA
[19]. While puzzling in light of the high structural similarity
between Hsp90 from C. elegans and B. pahangi, recent studies on
Hsp90 in human cancer and normal cells bring some molecular
insights into this paradox. Namely, it is becoming evident that a
complex array of co-chaperones and post-translational modifica-
tions modulate Hsp90 activity distinctly in each cellular context,
and these factors dictate the sensitivity of Hsp90 to small molecule
inhibitors such as GA [22].
While our previous findings position Hsp90 as a potential
target in killing both adults and Mf of B. pahangi, the use of GA as
a drug in treating these infections is prohibited by several
unfavorable chemical features. First, it exhibits severe hepato-
toxicity, which has been associated with the benzoquinone ring
and imposes strict dosing limitations. Secondly, it is metabolically
and chemically unstable. Also, it has very low solubility in
aqueous media resulting in formulations requiring DMSO [18].
In cancers, much effort has been directed at discovering novel
Hsp90-inhibitors of distinct chemical scaffold, and currently
several such agents are in pre-clinical or clinical evaluation
(reviewed in [23]). Similar efforts are required for the develop-
ment of agents targeted at Brugia Hsp90. Since the sensitivity to
Hsp90 inhibitors is determined by a complex crosstalk between
Hsp90 and the cellular environment, it is necessary to develop
screening strategies that account for the endogenous presentation
of Hsp90 in Brugia.
In this paper we describe an assay amenable for such a
screening strategy for inhibitors of filarial worm Hsp90. The assay
relies on fluorescence polarization (FP) and upon the ability of
inhibitors to block the binding of fluorescently labelled GA to
Hsp90 species characteristic of Brugia homogenates. We show that
the assay is specific and sensitive and able to detect compounds
that bind in the Brugia Hsp90 ATP pocket. The assay is suitable for
high-throughput screening, does not require the production of
purified recombinant protein and could be adapted to screen
Hsp90 inhibitors against other parasites, where Hsp90 is known to
be a valid target [24,25].
Methods
Reagents
Cy3B-GA was synthesized as previously reported [26,27] and
was dissolved in DMSO to form a 10 mM solution. GA, radicicol,
ivermectin and novobiocin were purchased from Sigma. The
assay buffer (HFB) contained 20 mM HEPES (K), pH 7.3,
50 mM KCl, 5 mM MgCl2,2 0 m MN a 2MoO4, and 0.01%
NP40. Before each use, 0.1 mg/mL bovine gamma globulin
(Panvera Corporation, Madison, WI) and 2 mM DTT (Fisher
Biotech, Fair Lawn, NJ) were freshly added. The synthesis and
characterization of PU-scaffold Hsp90 inhibitors is presented
elsewhere [27,28].
Preparation of worm extracts
Adult worms of B. pahangi were obtained from infected gerbils,
exactly as described previously [14] while C. elegans was cultured
on agar plates at 20uC [29]. Adult worms of B. pahangi or mixed
stage C. elegans worms were frozen in liquid nitrogen, ground in a
pestle and mortar to a fine powder and re-suspended in an
appropriate volume of HFB assay buffer. The protein concentra-
tion was estimated using the BioRad protein assay. At this point
lysates were freeze-dried for shipping to the USA. In some
experiments C. elegans hsp90 was knocked down by RNAi using the
standard bacterial feeding protocol [30], exactly as described
previously [20]. Control plates were seeded with HT115 cells
transformed with empty double T7 vector, L4440, while RNAi
plates were seeded with HT115 cells containing L4440 expressing
a 294 bp fragment of C. elegans daf-21 (hsp90). C. elegans L4 worms
were added to the plates and incubated at 20uC for 24 h, following
which worms were washed off the plates and processed for the FP
assay as described above. The efficiency of (hsp90)RNAi was
assessed by immunoblotting relative to the actin signal exactly as
described previously [31].
Human cancer cell lysate preparation
The human breast cancer cell line SKBr3 was obtained from
the American Type Culture Collection (Manassas, VA). Cells were
cultured in DME HG:F-12 medium supplemented with 10% fetal
bovine serum, NEAA, 1% penicillin, and streptomycin. Cells were
collected and frozen to rupture the membranes and then dissolved
in binding buffer with added protease and phosphotase inhibitors
to form the lysate. Lysates were stored at –80uC before use. Total
protein content was determined using the bicinchoninic acid assay
kit (Pierce Biotechnology, Rockford, IL) according to the
manufacturer’s instructions.
Author Summary
Helminth diseases of humans remain a major problem in
many parts of the tropics. Treatment of these parasitic
infections is restricted to a limited number of drugs and
few new compounds are in development. One of the
major obstacles to the development of new therapeutics is
the lack of high-throughput screens that can be adapted
to parasitic species for the identification of small molecule
inhibitors. Here we present a simple, inexpensive assay for
the identification of inhibitors of Hsp90 in filarial worms.
The assay, first described for the identification of Hsp90
inhibitors in tumor cells, does not require recombinant
protein but relies upon the ability of a fluorescently
labelled drug to bind to Hsp90 in the context of a soluble
fraction of worm homogenate. We validated the assay
using known inhibitors of Hsp90, including derivatives of
the synthetic purine-scaffold series of Hsp90 inhibitors and
were able to show a differential sensitivity to these
compounds between human and Brugia Hsp90.
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FP measurements were performed using black 96-well micro-
titer plates (Corning #3650), where both the excitation and the
emission occurred from the top of the well, on an Analyst GT plate
reader (Molecular Devices, Sunnyvale, CA). An integration time of
100 ms was used, and Z height was set at 3 mm (middle). The
excitation polarization was set at static, and the emission
polarization was set at dynamic. For cy3B-GA, an excitation filter
at 530 nm and an emission filter at 580 nm were used with a
dichroic mirror of 561 nm. All FP values were expressed in
millipolarization (mP) units. The mP values were calculated using
the equation mP =10006[(IS–ISB) – (IP–IPB)]/[(IS–ISB) +
(IP–IPB)], where IS is the parallel emission intensity
measurement, IP is the perpendicular emission intensity sample
measurement, and ISB and ISP are the corresponding measure-
ments for background (buffer). Total fluorescence was determined
as 26IP+IS.
Assay development and optimization
The Hsp90 FP assay was carried out in black 96-well
microplates in a total volume of 100 mL in each well. To
determine the equilibrium binding of cy3B-GA and worm lysates,
increasing amounts of lysates were incubated with 6 nM of cy3B-
GA. The plate was incubated at 4uC for different time periods,
and the FP in mP was measured with the Analyst GT.
To test the assay stability, the binding experiment was measured
after different incubation times at 4uC for up to 24 h. The assay
window was calculated as the difference between the FP value
recorded for the bound cy3B-GA and the FP value recorded for
the free cy3B-GA (defined as mP – mPf). Specific binding was
defined as the contribution of bound ligand to signal, and was
calculated as b 6mPb =m P–f 6mPf, where b and f are the
fractions of bound and free tracer, respectively; mP is the recorded
polarization value for a particular Hsp90 concentration; and mPf
is the polarization value for free tracer.
For assay performance, the signal-to-noise ratio (S:N) and the Z’
factor were calculated based on the following equations: S:N =
(mb – mf)/(SDb
2 + SDf
2)
0.5, where SDb and SDf are the standard
deviations for bound (b) (lysate + cy3B-GA) and free (f) cy3B-GA
(cy3B-GA only), respectively; mb – mf is the difference in mean
signals for bound and free cy3B-GA; and Z’ factor =1 – (3SDb +
3SDf)/(mb – mf), where the Z’ factor reflects the quality of the assay
itself without the intervention of test compounds [32].
Competition FP assays
For the competition studies, FP assays were performed as
previously reported [26]. Briefly, the Hsp90 inhibitors dissolved in
DMSO were added at several concentrations to the HFB assay
buffer containing both 6 nM cy3B-GA and nematode lysate (2 mg
B. pahangi lysate) or human cancer cell lysate (3 mg SKBr3 lysate) in
a final volume of 100 mL. Drugs were added to triplicate wells.
Free cy3B-GA (6 nM cy3B-GA), bound cy3B-GA (6 nM cy3B-GA +
lysate, as indicated above) and buffer only containing wells
(background) were included as controls in each plate. Plates were
incubated on a shaker at 4uC, and polarization values measured at
8 to 24 h. Percentage inhibition was calculated as follows: (%
Control) =100 – ((mPc –m P f)/(mPb –m P f))6100, where mPc is
the recorded mP from compound wells, mPf is the average
recorded mP from cy3B-GA–only wells, and mPb is the average
recorded mP from wells containing both cy3B-GA and lysate, and
plotted against values of competitor concentrations. The inhibitor
concentration at which 50% of bound cy3B-GA was displaced was
obtained by fitting the data using a nonlinear regression analysis as
implemented in Prism 4.0 (Graphpad Software).
Data analysis
All experimental data were analyzed using SOFTmax Pro 4.3.1
and plotted and analyzed using Prism 4.0 (Graphpad Software
Inc., San Diego, CA).
Effect of inhibitors on B. pahangi viability
Two inhibitors belonging to the purine-scaffold group of Hsp90
inhibitors, PU-H71 and PU-DZ8, were tested for their effects on
adult and microfilarial stages of B. pahangi exactly as described
previously [14]. Briefly, six adult female worms of B. pahangi were
cultured individually in 24-well plates in RPMI-1640 with 10%
heat inactivated foetal calf serum containing drug, carrier alone at
the appropriate concentration (DMSO) or as a positive control,
GA at 1.0 mM. Compounds PU-H71 and PU-DZ8 were tested at
the indicated concentrations. Mf output by individual female
worms was assessed at two time points and adult worms were
examined microscopically and their condition noted. Results are
expressed as mean Mf output over a three-day period 6 SD.
Statistical significance between groups was calculated using the
Mann Whitney test with P values ,0.05 being considered
significant.
Results
Brugia pahangi assay development
To measure the affinity of cy3B labelled GA to Hsp90 species
characteristic of Brugia, we took advantage of an FP assay
developed for tumor cell Hsp90 [33]. FP is based on the
observation that when a relatively small, fast-tumbling fluorescent
labeled compound (in this case a fluorescently labeled GA
molecule) is excited with plane-polarized light, the emitted light
is random with respect to the plane of polarization, resulting in a
lower mP value. When the compound is bound to a bigger
molecule (in this case Hsp90), the complex tumbles more slowly
and the emitted light is polarized, resulting in a higher mP value.
Thus, the change in mP reflects the interaction between the
labeled compound (i.e. fluorescent GA) and the protein (i.e.
Hsp90). The mP value is proportional to the fraction of bound
ligand and the assay is very powerful in measuring real-time
protein–inhibitor interactions in solution.
Here we investigated whether the FP assay could be applied to a
more complex, multicellular species such as a nematode worm. To
investigate this possibility, we prepared extracts from B. pahangi
and from the GA-insensitive nematode C. elegans, and probed the
affinity of the fluorescent GA molecule, cy3B-GA, for the Hsp90
species characteristic of these two nematodes (Figure 1). For an FP
assay to be useful, the binding affinity of the fluorescent ligand to
the protein should be high and the binding range or the assay
window (maximum mP at saturation - minimal mP at no protein)
should be large (.100 mP). Rewardingly, cy3B-GA bound to the
Brugia Hsp90 species (Figure 1A) with a high affinity, similar to the
tumor Hsp90 species (Figure 1B). At reduced lysate concentra-
tions, a low mP value was obtained for both extracts; as the
concentration of lysate increased, a greater fraction of fluorescent
GA bound to Hsp90 species and polarization progressively
increased to reach saturation. The signal amplified with time,
reached equilibrium at 8 h and remained stable thereafter,
resulting in an excellent assay window of approximately 200 mP
(Figure 1A). In contrast, cy3B-GA bound the C. elegans extracts
with very low affinity (Figure 1C). The signal at each time point
was virtually indistinguishable from time 0, indicating that the low
increase in mP, observed especially at high extract concentrations,
was caused by non-specific binding of the tracer or by
autofluorescence from the worm extract. This conclusion was
Hsp90 Inhibitors and Brugia pahangi
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where Hsp90 levels were reduced by ,40% by means of RNAi
(data not shown), showed essentially no change in binding signal
(Figure 1C). These assay results concord well with previous
observations that despite a high degree of conservation between
the two nematode Hsp90 sequences [20] and an essentially
overlapping binding mode predicted computationally (Figure 1D),
GA has no significant effect on C. elegans [19].
Analysis of the binding curve at equilibrium, as demonstrated
by specific binding (Figure 2A) and Scatchard and Hill plot
analyses (Figure 2B and data not shown) demonstrated that at the
low lysate amounts required to reach saturation, the interaction
from other cellular material was precluded. Even at 1.5–2.5 mg
Brugia extract, more than 95% to 99% of cy3B-GA was Hsp90-
bound (Figure 2C).
To evaluate the applicability of the 96-well FP assay for HTS,
the assay performance parameters S:N and Z’ were determined to
be 32 and 0.87, respectively (Figure 2D). For FP, a S:N value
higher than 8 is recommended for reliable readings. The Z’ factor
is a parameter for the quality of the assay itself without test
compounds. Assays with a Z’ factor between 0.5 and 1.0 are
considered to be reliable, robust, and suitable for HTS [32].
Brugia pahangi assay validation
To further demonstrate the specificity of the recorded signal for
Hsp90, we conducted several competitive assays (Figure 3). As
expected, unlabelled GA displaced cy3B-GA binding to Brugia
extracts in a dose-dependent manner, resulting in near 100%
displacement at 250–500 nM (Figure 3A). The competitive assay
signal remained constant over the recorded interval of 8 to 24 h
(Figure 3A). Only competitive binders of the N-terminal binding
site of Hsp90, such as GA, radicicol and the endogenous ligand
ADP, resulted in dose-dependent reduction of the FP signal
(Figure 3B). In contrast, the Hsp90 C-terminal interactor,
novobiocin, or the anthelmintic ivermectin had no such effect.
Next we evaluated two derivatives of the purine-scaffold class, a
chemotype distinct from that of the natural products GA and
radicicol [34]. PU-H71 and PU-DZ8, representative of the purine-
scaffold compounds, are fully synthetic molecules that were
rationally designed to bind to the N-terminal site ATP pocket of
Hsp90. Both agents inhibited the binding of cy3B-GA to Brugia
Hsp90, albeit with a potency 4- to 8-fold lower than GA,
respectively (IC50
PU-H71 =80 nM and IC50
PU-DZ8 =160 nM vs
IC50
GA =20 nM) (Figure 3C).
To investigate whether the results of the FP assay correlate with
the effects of Hsp90 inhibitors on Brugia viability and Mf output,
the effect of two PU-scaffold compounds on worm viability was
assessed. Adult female worms of B. pahangi were incubated in
medium containing either GA at 1 mM [14], or the two synthetic
inhibitors PU-H71 and PU-DZ8 at 5 and 10 mM. All agents had a
profound effect on Mf release (Figure 3D), with a trend in potency
that followed their affinity for Brugia Hsp90 (GA . PU-H71 .
PU-DZ8 see Figure 3C). Adult worms were markedly less active in
10 mM and 5.0 mM PU-H71 and 10 mM PU-DZ8, but there was
less of an effect at 5.0 mM PU-DZ8. In the wells that were affected,
the adult worms become elongate and immobilised, very similar to
the reported effects of GA on adult Brugia. This experiment was
repeated on two additional occasions with similar results. In a
further experiment, adult worms were exposed to the most potent
of the purine-scaffold compounds, PU-H71, at 5.0 and 2.5 mM
and to GA at 1.0 mM and Mf production assessed. The most
significant reductions in Mf output were observed at 1.0 mMG A
Figure 1. Brugia assay development. (A–C) Dose-response curve for the binding of 6 nM cy3B-GA to Hsp90 present in the adult Brugia pahangi
worm extract (A), SKBr3 cell lysate (B) and C. elegans extract (-RNAi) or to a C. elegans extract in which hsp90 had been depleted by RNAi by
approximately 40% (+RNAi) (C) Various amounts of total lysate protein dissolved in binding buffer (0–20 mg/well) were incubated in triplicate wells
with the ligand at 4uC, and the response was measured at the indicated time intervals. Fluorescence polarization was read with an Analyst GT
instrument. Values obtained at several time intervals were plotted against the amount of added total protein. The assay window data were obtained
by subtracting free tracer values from values recorded in the presence of specified protein concentrations. Data were analyzed and plotted in Prism
4.0. Points, mean; bars, s.d. (D) Overlay of GA-bound homology models (derived using Prime software of Schrodinger L.L.C, NY) of B. pahangi (orange,
Accession number AJ005784) and C. elegans (green, Accession number Z75530) and the X-ray crystal structure of human Hsp90a (blue, PDB ID: 1YET).
doi:10.1371/journal.pntd.0000714.g001
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output, while still significant, was less pronounced (see Figure 3D).
In separate experiments, Mf were purified from the peritoneal
cavity of infected animals and incubated alone in each of the
drugs. At 10 mM PU-H71, 100% of worms were dead by day 7
and at 5.0 mM PU-H71, approximately 80% of worms were dead
by day 7. For 10 mM PU-DZ8 at day 7, ,95% of worms were
dead with 50% mortality at 5.0 mM. In the control wells there was
,5% mortality at these times, while Mf incubated with GA
(1.0 mM) were all dead.
To evaluate whether the assay is sufficiently sensitive to
differentiate between human and Brugia Hsp90 species, and thus
lead to the identification of species-selective inhibitors, we
measured the affinity of GA and of several closely related PU-
class derivatives, PU-24FCl, PU-H71 and PU-WS10 for the Brugia
(Figure 4A) and the SKBr3 (Figure 4B) Hsp90 complexes. While
GA interacted with identical affinity with both human and Brugia
species, a good selectivity was noted in the PU-series, with a
selectivity ratio of 2, 3.5 and 9 for PU-24FCl, PU-H71 and PU-
WS10, respectively (Figure 4C). The 3-fold change in selectivity
ratio between PU-H71 and PU-WS10, two agents of almost
identical chemical structure, further confirms the sensitivity of the
Hsp90 pocket to the cellular environment and suggests that it may
be possible to identify molecules that specifically target the parasite
Hsp90.
Discussion
Although high-throughput screening is now well established for
the identification of small molecules with novel activities in many
human diseases, relatively little attention has been paid to the
application of such methods to the neglected tropical diseases of
humans [35,36]. Consequently the development of novel thera-
peutics for most of these diseases has lagged behind other areas. In
an attempt to redress that balance, several academic institutes and
public-private partnerships have developed screening programmes
which are beginning to bear fruit [37]. Notable recent successes
are the identification of the oxadiazoles for the control of
schistosomiasis [38] the development of kinase inhibitors for the
chemotherapy of malaria [39], and the identification of a range of
targets for Trypanosoma brucei (reviewed in [40]). A recent paper also
demonstrated promising results using an existing chemical library
to screen against a novel target in filarial worms. Here it was
shown that the veterinary anthelmintic, closantel, had activity
against a chitinase from the filarial nematode, Onchocerca volvulus
[41]. In this paper we describe the application of an assay
developed for the identification of inhibitors of tumor cell Hsp90
to the parasitic nematode Brugia. Through its simple mix-and-read
format, and the use of low amounts of fluorophore and cell
homogenates, the FP assay is low-cost and thus highly amenable
for high-throughput screening. Cy3B is a red-shifted dye that has
been found to be particularly well suited for FP due to its increased
fluorescence intensity, fluorescence lifetime of 2.9 ns, and stability
of its signal in a variety of aqueous solvent conditions. In addition,
its use in the labeling of GA may limit the potential interference of
fluorescent small-molecule library components and reduce false-
positives resulting from light scattering caused by insoluble
compounds.
Instead of recombinant protein, the original tumor cell Hsp90
assay made use of human cancer cell lysates, but nonetheless,
could selectively probe the interaction of small molecules with
cancer cell-specific Hsp90 by taking advantage of the specificity of
GA for tumor Hsp90 species. While its use is now validated in
several tumor cell extracts [42,43], it remained unclear whether it
could be applied to extracts of complex multicellular organisms.
Here we demonstrate the applicability of this screen to the
Figure 2. Analysis of Brugia assay performance. (A–C) Data collected at equilibrium in the binding experiment described in Fig1A were
transformed and analyzed using a nonlinear regression method in Prism 4.0, and Hill plots were constructed. Specific binding represents the
contribution of bound ligand to total recorded values. (D) Two 96-well plates each containing 48 free tracer control wells (6 nM cy3B-GA) and 48
bound tracer control wells (6 nM cy3B–GA with added lysate, 2 mg/well) were used to determine the suitability of the assay for high-throughput
screening. The millipolarization value for each well was recorded, and average values corresponding to each plate were plotted. The signal-to-noise
ratios and the Z’ factors were calculated as indicated in Methods.
doi:10.1371/journal.pntd.0000714.g002
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similar kinetics to lysates prepared from adult B. pahangi and to
extracts of tumor cells. Previous studies have shown that Hsp90 in
normal cells possesses a very low affinity for inhibitors such as
PU24FCl (10–50 fold less compared to tumor cell Hsp90) [44] or
GA [22]. This precludes a direct comparison in the FP assay of
Brugia Hsp90 with that found in normal tissues, but does suggest
that Hsp90 inhibitors could have a selective effect on the parasite.
Binding to Brugia Hsp90 was specific and could be inhibited by
small molecules that bind in the N-terminal ATP pocket of Hsp90,
thus validating the potential of the assay as a HTS for novel
inhibitors of Hsp90. Several studies have now shown that Hsp90
from the free-living nematode C. elegans has a low affinity for GA in
pull-down assays [14,19,31] and the assay was further validated by
the inability of C. elegans extracts to bind cy3b-GA. The molecular
basis of the differing sensitivities of nematode Hsp90s to N-
terminal inhibitors has not been resolved but may reflect
differences in post-translational modification of Hsp90, or
interactions with different co-chaperones or client proteins [31].
Hsp90 is an attractive target in tumor cells for a number of
reasons: because of the interaction of Hsp90 with a range of
essential client proteins, inhibition of a single molecular species
inhibits multiple pathways [45], which may reduce the likelihood
of resistance developing. While nothing is currently known of
Hsp90 clients in Brugia, yeast two-hybrid screens and analysis of
genetic interactions have identified a number of likely Hsp90
targets in C. elegans (http://www.wormbase.org/db/gene/
interaction?list=WBGene00000915), including transcription fac-
tors, nuclear hormone receptors and kinases. Efforts are currently
on-going to identify Hsp90 clients in Brugia. Secondly, Hsp90 in
tumor cells appears to have an increased affinity for drugs such as
GA, a phenomenon which may relate to the conformation of
Hsp90 in multi-chaperone complexes in tumor cells compared to
normal cells, where it exists in a free uncomplexed state [22]. It is
interesting to note that the affinity of Brugia Hsp90 for GA in this
study was very similar to tumor cell Hsp90, but our studies
indicated that other inhibitor classes, such as the purine-scaffold
series, have different affinities for Brugia Hsp90 and human cellular
Hsp90. This suggests that Brugia Hsp90 may be selectively targeted
and supports HTS efforts towards the identification of novel
chemotypes with enhanced potency and selectivity. The purine-
scaffold derivatives used to elucidate the potential selectivity for the
human and Brugia Hsp90 species have been extensively tested both
in vitro and in vivo. These studies, together with relevant drug
metabolism and pharmacokinetic analyses, demonstrate no
liability with respect to chemical stability [34,43,44]. There are
several other Hsp90 inhibitors in development [18], including
molecules based on radicicol [46], which also targets the N’-
terminal ATP pocket, or novobiocin [47], an inhibitor that binds
at the C’-terminus of Hsp90, with a completely different mode of
action to GA [48].
The concentration of drug required to kill adult Brugia (500 nM
for GA, 2.5 mM for PU-H71) was significantly higher than the
IC50 calculated from the FP assay. In part, this may reflect issues
related to the uptake of drug by adult worms. At least in vitro,i ti s
probable that small molecules are taken up across the cuticle [49],
while in vivo the intestine is functional [50]. Little is known of the
factors that influence the permeability of the filarial cuticle to small
Figure 3. Brugia assay validation. (A–C) Increasing concentrations of indicated inhibitors were added in triplicate to the reaction buffer
containing 6 nM of cy3B-GA and Brugia extracts (2 mg/well) in a final volume of 100 mL. Free (6 nM cy3B-GA) and bound (6 nM cy3B-GA with 2 mg/
well Brugia extract) controls were included on each plate. The polarization values were measured after incubation at 4uC for the indicated times to
evaluate assay stability (A) or for 24 h with the indicated inhibitors to evaluate their affinity for Brugia Hsp90 (B, C). The competitive effect was
expressed as percentage of control and was calculated by dividing the millipolarization (mP; subtracting free cy3B-GA) value from inhibitor wells by
the average mP (subtracting free cy3B-GA) from controls (cy3B-GA and cell lysate with vehicle DMSO) in each plate. Ligand binding was plotted
against the log10 inhibitor concentration, and EC50 values were calculated using a nonlinear least-square curve-fitting program in Prism 4.0. Points,
mean; bars, s.d. (D) Six adult female B. pahangi were incubated individually in 2.0 ml of tissue culture medium containing GA at 1.0 mM, PU-H71 at 10,
5 or 2.5 mM, PU-DZ8 at 10 or 5 mM, DMSO or medium alone. Graphs show mean and SD of Mf output over a three-day period from six female worms
per group. Data combined from two separate experiments. *** P,0.005 for all drug concentrations vs DMSO except for PU-H71 at 2.5 mM where
P=0.0260 (**).
doi:10.1371/journal.pntd.0000714.g003
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of methylation of peptides are important determinants of
transcuticular uptake in an in vitro system [51]. However, the
rapid onset of GA-induced effects in adult worms (Mf output being
affected within 24 h, [14]) indicates the efficient absorption of
drug.
In conclusion we have demonstrated that a HTS developed for
tumor cell Hsp90 is applicable to an important parasitic species,
Brugia. Thus far the assay has been validated using a small number
of compounds that compete with labelled GA for binding to the
Brugia Hsp90 N-terminal ATP binding pocket. Hsp90s are
generally highly conserved and nematodes are no exception
[31]. Hsp90 from B. malayi is 99.7% identical to B. pahangi Hsp90,
validating the use of the model species in a screen for compounds
that will target the human parasite. Given the format of the assay,
the ability to utilise whole worm extracts and the relatively modest
cost, the FP assay could now be applied to the identification of
novel inhibitors of Brugia Hsp90 or adapted for other parasites
where Hsp90 is a possible target, such as Plasmodium falciparum [25]
and other important pathogens [52].
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